Note: Ingredients listed on restricted chemical lists
EC/CAS
1303-96-4
Name of the chemical
Disodium tetraborate, anhydrous
Concentration
N/A
EC/CAS
10043-35-3
Name of the chemical
Borsäure Borsäure
Concentration
N/A
EC/CAS
7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
N/A
EC/CAS
7647-01-0
Name of the chemical
Hydrochloric acid
Concentration
N/A
General Information
Revision date
2024-08-06
Product name
Brimonidine Tartrate Ophthalmic Solution, 0.1%
Product Synonyms
Brimonidine Tartrate Ophthalmic drops
1.2.1 Relevant identified uses
Alpha-Adrenergic Receptor Intra-ocular Pressure (IOP
Icons in SDS
Company Information
company name
Somerset Therapeutics
Section 2
SECTION 2: Hazards identification
OSHA Hazards Classification
2.2 Label elements
Emergency Overview The product contains no substances which at their given concentration, are considered to be hazardous to health Appearance Liquid Physical state Liquid Odor Slight Chemical Name Potassium Chloride Symptoms The most common adverse reactions to potassium chloride are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarhhea. One the most severe adverse side effects is hyperkalemia, There have also been reports of upper and lower gastrointestinal conditions including obstruction, bleeding, ulceration, and perforation. Brimonidine tartrate Prolonged or repeated exposure can cause central nervous system effects. allergic conjunctivitis, burning sensation, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, hypertension, ocular allergic reaction, oral dryness, and visual disturbance. Chemical Name Potassium Chloride
Medical Conditions Generally Aggravated by Exposure
Contraindications occur in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate the following conditions: chronic renal failure, systemic acidosis, acute dehydration, extensive tissue beak down and adrenal insufficiency. Other contraindications occur in any patient in whom there is structural, pathological or pharmacologic cause for arrest or delay in tablet passage Brimonidine tartrate through the gastrointestinal tract. Antihypertensives/cardiac glycosides may lower blood pressure. Use with CNS depressants may result in an additive or potentiating effect. Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine. Monoamine oxidase inhibitors may result in increased hypotension.
Further information
Unknown Acute Toxicity 99.9% of the mixture consists of ingredient(s) of unknown toxicity
2.1 Classification of the substance or mixture
OSHA Regulatory Status This chemical is not considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.122) Not a dangerous substance or mixture according to the Globally Harmonized System (GHS)